Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1494-1500

  Nuciforo, Paolo G ^a   Aura, C ^a   Holmes, E ^b   Prudkin, L ^a   Jimenez, J ^a   Martinez, P ^a   Ameels, H ^c   De La Pena L ^d   Ellis, C ^e   Eidtmann, H ^f   Piccart Gebhart, M J ^c   Scaltriti, M ^g   Baselga, J ^g  

^a VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^b FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^c JULES BORDET INSTITUTE   (Belgium)

^d Solti Breast Cancer Research Group   (Spain)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breast cancer; HER2 positive; Lapatinib; PIK3CA; PTEN; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; EARLY CANCER; ENZYME ACTIVATION; EVENT FREE SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHROMOSOME 10; CLINICAL TRIAL; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENE DELETION; GENETICS; METABOLISM; MULTICENTER STUDY; NEOADJUVANT THERAPY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDY; REMISSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 10; FEMALE; FOLLOW-UP STUDIES; GENE DELETION; HUMANS; IMMUNOENZYME TECHNIQUES; NEOADJUVANT THERAPY; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, ERBB-2; REMISSION INDUCTION; TRASTUZUMAB;

EID: 84940187385     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv175     Document Type: Article

References (26)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-182.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
4. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
5. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
6. De P, Hasmann M, Leyland-Jones B. Molecular determinants of trastuzumab efficacy: what is their clinical relevance? Cancer Treat Rev 2013; 39:925-934.
7. Majewski I, Nuciforo P, Mittempergher L et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant HER2-targeted therapies in breast cancer. J Clin Oncol 2015; 33: 1334-1339.
8. Eichhorn PJ, Gili M, Scaltriti M et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-9230.
9. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402.
10. Faratian D, Goltsov A, Lebedeva G et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res 2009; 69: 6713-6720.
11. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
12. Dave B, Migliaccio I, Gutierrez MC et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011; 29: 166-173.
13. Perez EA, Dueck AC, McCullough AE et al. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol 2013; 31: 2115-2122.
14. Xu B, Guan Z, Shen Z et al. Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2 positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone. Breast Cancer Res 2014; 16: 405.
15. Yonemori K, Tsuta K, Shimizu C et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 2009; 26: 344-349.
16. Jensen JD, Knoop A, Laenkholm AV et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 2012; 23: 2034-2042.
17. Esteva FJ, Guo H, Zhang S et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status:association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010; 177: 1647-1656.
18. Baselga J, Cortes J, Im SA et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 2014; 32: 3753-3761.
19. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2- positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
20. de Azambuja E, Holmes AP, Piccart-Gebhart M et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014; 15:1137-1146.
21. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384:164-172.
22. Perez-Tenorio G, Alkhori L, Olsson B et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res 2007; 13: 3577-3584.
23. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2- positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
24. Loibl S, Darb-Esfahani S, Klimowicz A et al. PTEN and PIK3CA but not p4EBP1 are associated with low rates of pathological complete response (pCR) to trastuzumab based chemotherapy in primary HER2-overexpressing breast cancer. In: Poster presented at the 37th San Antonio Breast Cancer Symposium, 9-13 December. San Antonio, TX, 2014.
25. Sangale Z, Prass C, Carlson A et al. A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol 2011; 19: 173-183.
26. Loibl S, von Minckwitz G, Schneeweiss A et al. PIK3CA Mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer. J Clin Oncol 2014; 32: 3212-3220.